CA2663791C - Pyrazolo (1, 5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors - Google Patents

Pyrazolo (1, 5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors Download PDF

Info

Publication number
CA2663791C
CA2663791C CA2663791A CA2663791A CA2663791C CA 2663791 C CA2663791 C CA 2663791C CA 2663791 A CA2663791 A CA 2663791A CA 2663791 A CA2663791 A CA 2663791A CA 2663791 C CA2663791 C CA 2663791C
Authority
CA
Canada
Prior art keywords
amino
phenyl
pyrazolo
triazin
diaza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2663791A
Other languages
English (en)
French (fr)
Other versions
CA2663791A1 (en
Inventor
Shaosong Chu
Zhe Nie
Carin L. Perretta
Philip Eugene Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polaris Group Taiwan
Original Assignee
Polaris Group Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polaris Group Taiwan filed Critical Polaris Group Taiwan
Publication of CA2663791A1 publication Critical patent/CA2663791A1/en
Application granted granted Critical
Publication of CA2663791C publication Critical patent/CA2663791C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2663791A 2006-09-18 2007-09-18 Pyrazolo (1, 5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors Expired - Fee Related CA2663791C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84531406P 2006-09-18 2006-09-18
US60/845,314 2006-09-18
US11/856,476 US7517882B2 (en) 2006-09-18 2007-09-17 Protein kinase inhibitors
US11/856,476 2007-09-17
PCT/US2007/020231 WO2008036277A1 (en) 2006-09-18 2007-09-18 Pyraz0l0(l,5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CA2663791A1 CA2663791A1 (en) 2008-03-27
CA2663791C true CA2663791C (en) 2015-11-03

Family

ID=39052753

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2663791A Expired - Fee Related CA2663791C (en) 2006-09-18 2007-09-18 Pyrazolo (1, 5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors

Country Status (11)

Country Link
US (2) US7517882B2 (enExample)
EP (1) EP2064214B1 (enExample)
JP (1) JP5232786B2 (enExample)
KR (1) KR101418619B1 (enExample)
CN (1) CN101522683B (enExample)
AU (1) AU2007297675B2 (enExample)
BR (1) BRPI0718459A2 (enExample)
CA (1) CA2663791C (enExample)
ES (1) ES2400450T3 (enExample)
TW (1) TWI472530B (enExample)
WO (1) WO2008036277A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
AU2009233963B2 (en) * 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
KR20140078710A (ko) * 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제
CN105209040A (zh) * 2013-03-15 2015-12-30 昂科迪塞恩股份有限公司 大环的盐可诱导的激酶抑制剂
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
JP6789962B2 (ja) * 2015-03-09 2020-11-25 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体
RU2019105587A (ru) * 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
JP7586829B2 (ja) * 2019-03-11 2024-11-19 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
SG11202110523XA (en) * 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US7482354B2 (en) * 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MXPA06013996A (es) * 2004-06-02 2007-02-08 Takeda Pharmaceutical Compuesto heterociclico fusionado.
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors

Also Published As

Publication number Publication date
KR101418619B1 (ko) 2014-07-14
JP2010503690A (ja) 2010-02-04
TWI472530B (zh) 2015-02-11
CN101522683B (zh) 2013-02-27
US20080070893A1 (en) 2008-03-20
KR20090083889A (ko) 2009-08-04
WO2008036277A1 (en) 2008-03-27
US7517882B2 (en) 2009-04-14
AU2007297675A1 (en) 2008-03-27
CA2663791A1 (en) 2008-03-27
EP2064214A1 (en) 2009-06-03
ES2400450T3 (es) 2013-04-10
TW200837065A (en) 2008-09-16
BRPI0718459A2 (pt) 2013-12-03
EP2064214B1 (en) 2013-01-30
AU2007297675B2 (en) 2012-09-20
CN101522683A (zh) 2009-09-02
JP5232786B2 (ja) 2013-07-10
US20090247501A1 (en) 2009-10-01
HK1135688A1 (en) 2010-06-11

Similar Documents

Publication Publication Date Title
CA2663791C (en) Pyrazolo (1, 5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors
US10208051B2 (en) Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
AU2007316417B2 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
AU2007332440B2 (en) Quinoxaline derivative
AU2010214095B2 (en) Novel amino azaheterocyclic carboxamides
CN109721600A (zh) 一类含氮稠环化合物及其制备方法和用途
KR20110028445A (ko) 퇴행성 및 염증성 질병의 치료에 유용한 축합된 피라진 화합물
AU2011299936A1 (en) Quinoxaline compound
EP2794571B1 (en) Novel heterocyclic carboxamides as modulators of kinase activity
CN117645598A (zh) 氮杂二并多元稠环化合物及其药物组合物和应用
Liang et al. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors
PL236355B1 (pl) Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
HK1135688B (en) Pyrazolo (1,5-a)(1,3,5) triazine and pyrazolo (1,5-a) pyrimidine derivatives useful as protein kinase inhibitors
CN119285624B (zh) 一种含噻吩的嘧啶类化合物及其制备方法与在制备具有抗癌作用的药物中的应用
Khodairy et al. Hetarylcyanamides: Synthesis of Novel Thiazole, Triazole and Pyrimidine Derivatives and Prediction of their Biological Activity via PASS Inet
AU2022378269A1 (en) Quinazoline derivative compound and use thereof
TW202409037A (zh) 嘧啶衍生物
HK1178534A (en) Pyrrolopyrazine derivatives and their use as jak and syk inhibitors
HK1183302A1 (zh) 作为激酶p70s6k抑制剂的二环氮杂环甲酰胺

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200918